The Food and Drug Administration has approved the first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets.
Lisdexamfetamine dimesylate capsules and chewable tablets are indicated for attention-deficit/hyperactivity disorder (ADHD) in patients 6 years of age and older, and for moderate to severe binge-eating disorder (BED) in adults.
The approvals were granted to various manufacturers. Like the brand, the prescribing information for lisdexamfetamine dimesylate capsules and chewable tablets contains a Boxed Warning informing health care providers and patients about the potential risk of abuse and dependence.
Continue Reading
Reference
US Food and Drug Administration. FDA approves multiple generics of ADHD and BED treatment. News release. Accessed August 28, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment?utm_medium=email&utm_source=govdelivery.
This article originally appeared on MPR
